Four versus Two Years of Rituximab Maintenance (R-Maintenance) Following Bendamustine Plus Rituximab (B-R): Results of a Prospective, Randomized Multicenter Phase 3 Study in First-Line Follicular Lymphoma (the StiL NHL7-2008 MAINTAIN Study)

被引：3
|
作者：
Rummel, Mathias [1 ]
Buske, Christian [2 ]
Hertenstein, Bernd [3 ]
Lerchenmueller, Christian [4 ]
Koenigsmann, Michael [5 ]
Lange, Elisabeth [6 ]
Reeb, Manfred [7 ]
Kaiser, Ulrich [8 ]
Balser, Christina
Behringer, Dirk [9 ]
Duerig, Jan [10 ]
Gaska, Tobias [11 ]
Maschmeyer, Georg [12 ]
Schliesser, Georg
Burchardt, Alexander C. [1 ]
Barth, Juergen [1 ]
Kauff, Frank [1 ]
Hinke, Axel [13 ]
Greil, Richard [14 ]
机构：
[1] Univ Hosp Giessen, Med Clin 4, Hematol, Giessen, Germany
[2] Univ Hosp Ulm, Comprehens Canc Ctr Ulm, Inst Expt Canc Res, Ulm, Germany
[3] Klinikum Bremen Mitte, Med Klin 1, Bremen, Germany
[4] Outpatient Clin, Hematol & Oncol, Munster, Germany
[5] Outpatient Oncol Ctr, Hannover, Germany
[6] Evangel Krankenhaus Hamm, Hamm, Germany
[7] IDGGQ GbR, Kaiserslautern, Germany
[8] St Bernward Hosp, Hildesheim, Germany
[9] Augusta Kranken Anstalt gGmbH Bochum, Dept Haematol Oncol & Palliat Care, Bochum, Germany
[10] Univ Hosp Essen, Dept Haematol, Essen, Germany
[11] Bruderkrankenhaus St Josef, Hematol & Oncol, Paderborn, Germany
[12] Klinikum Ernst von Bergmann, Potsdam, Germany
[13] CCRC, Dusseldorf, Germany
[14] Univ Hosp Salzburg, Salzburg, Austria
来源：
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA | 2018年 / 18卷
关键词：
Indolent lymphoma; non-hodgkin-lymphoma; Bendamustine; Rituximab maintenance;
D O I：
10.1016/j.clml.2018.06.072
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
FR-S26-NHL
引用
收藏
页码：S101 / S103
页数：3
相关论文
共 49 条
  • [1] Four versus two years of Rituximab maintenance (R-maintenance) following Bendamustine plus Rituximab (B-R): initial results of a prospective, randomized multicenter phase 3 study in first-line follicular lymphoma (the StiL NHL7-2008 MAINTAIN study)
    Rummel, M.
    Buske, C.
    Hertenstein, B.
    Lerchenmueller, C. A.
    Koenigsmann, M.
    Lange, E.
    Reeb, M.
    Kaiser, U.
    Balser, C.
    Behringer, D.
    Duerig, J.
    Gaska, T.
    Maschmeyer, G.
    Schliesser, G.
    Burchardt, A.
    Barth, J.
    Kauff, F.
    Hinke, A.
    Greil, R.
    ONCOLOGY RESEARCH AND TREATMENT, 2018, 41 : 251 - 251
  • [2] Four Versus Two Years of Rituximab Maintenance (R-maintenance) Following Bendamustine Plus Rituximab (B-R): Initial Results of a Prospective, Randomized Multicenter Phase 3 Study in First-Line Follicular Lymphoma (the StiL NHL7-2008 MAINTAIN study)
    Rummel, Mathias J.
    Buske, Christian
    Hertenstein, Bernd
    Lerchenmueller, Christian
    Koenigsmann, Michael
    Lange, Elisabeth
    Reeb, Manfred
    Kaiser, Ulrich
    Balser, Christina
    Behringer, Dirk
    Durig, Jan
    Gaska, Tobias
    Maschmeyer, Georg
    Schliesser, Georg
    Burchardt, Alexander Christoph
    Barth, Juergen
    Kauff, Frank
    Hinke, Axel
    Greil, Richard
    BLOOD, 2017, 130
  • [3] Two years rituximab maintenance vs. observation after first-line treatment with bendamustine plus rituximab (B-R) in patients with mantle cell lymphoma: First results of a prospective, randomized, multicenter phase II study (a subgroup study of the StiL NHL7-2008 MAINTAIN trial).
    Rummel, Mathias J.
    Knauf, Wolfgang
    Goerner, Martin
    Soeling, Ulrike
    Lange, Elisabeth
    Hertenstein, Bernd
    Eggert, Jochen
    Schliesser, Georg C.
    Weide, Rudolf
    Blumenstengel, Klaus
    Detlefsen, Ninia
    Hinke, Axel
    Kauff, Frank
    Barth, Juergen
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [4] Two years rituximab maintenance vs. observation after first line treatment with bendamustine plus rituximab (B-R) in patients with marginal zone lymphoma (MZL): Results of a prospective, randomized, multicenter phase 2 study (the StiL NHL7-2008 MAINTAIN trial).
    Rummel, Mathias J.
    Koenigsmann, Michael
    Chow, Kai Uwe
    Knauf, Wolfgang
    Lerchenmuller, Christian A.
    Losem, Christoph
    Goerner, Martin
    Hertenstein, Bernd
    Decker, Thomas
    Ganser, Arnold
    Gaska, Tobias
    Heike, Michael
    Lange, Elisabeth
    Weide, Rudolf
    Willenbacher, Wolfgang
    Burchardt, Alexander
    Kauff, Frank
    Barth, Juergen
    Hinke, Axel
    Greil, Richard
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [5] Two years Rituximab maintenance vs. observation after first line treatment with bendamustine plus rituximab (B-R) in patients with marginal zone lymphoma (MZL): results of a prospective, randomized, multicenter phase 2 study (the StiL NHL7-2008 MAINTAIN trial)
    Rummel, M.
    Koenigsmann, M.
    Chow, K. U.
    Knauf, W.
    Lerchenmueller, C. A.
    Losem, C.
    Goerner, M.
    Hertenstein, B.
    Decker, T.
    Ganser, A.
    Gaska, T.
    Heike, M.
    Lange, E.
    Weide, R.
    Willenbacher, W.
    Burchardt, A.
    Kauff, F.
    Barth, J.
    Hinke, A.
    Greil, R.
    ONCOLOGY RESEARCH AND TREATMENT, 2018, 41 : 253 - 253
  • [6] Two Years Rituximab Maintenance Vs. Observation after First Line Treatment with Bendamustine Plus Rituximab (B-R) in Patients with Waldenstrom's Macroglobulinemia (MW): Results of a Prospective, Randomized, Multicenter Phase 3 Study (the StiL NHL7-2008 MAINTAIN trial)
    Rummel, Mathias J.
    Lerchenmueller, Christian
    Hensel, Manfred
    Goerner, Martin
    Buske, Christian
    Schulz, Holger
    Schmidt, Burkhard
    Kojouharoff, Georgi
    Lange, Elisabeth
    Willenbacher, Wolfgang
    Durig, Jan
    Engel, Erik
    Kauff, Frank
    Barth, Jurgen
    Burchardt, Alexander Christoph
    Hinke, Axel
    Wupperfeld, Jasmin
    Greil, Richard
    BLOOD, 2019, 134
  • [7] Two Years Rituximab Maintenance Vs Observation After First Line Treatment With Bendamustine Plus Rituximab in Patients With Waldenstrom's Macroglobulinemia: Results of a Prospective, Randomized, Multicenter Phase 3 Study (the StiL NHL7-2008 MAINTAIN trial)
    不详
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2020, 18 (02) : 23 - 23
  • [8] Two years Rituximab maintenance vs. observation after first line treatment with bendamustine plus rituximab (B-R) in patients with mantle cell lymphoma: first results of a prospective, randomized, multicenter phase 2 study (a subgroup study of the StiL NHL7-2008 MAINTAIN trial; Clinicaltrials.gov Identifier: NCT00877214)
    Rummel, M.
    Knauf, W.
    Goemer, M.
    Soeling, U.
    Lange, E.
    Hertenstein, B.
    Eggert, J.
    Schliesser, G. C.
    Weide, R.
    Blumenstengel, K.
    Detlefsen, N.
    Hinke, A.
    Kauff, F.
    Barth, J.
    ONCOLOGY RESEARCH AND TREATMENT, 2016, 39 : 118 - 118
  • [9] 10-year updated results from the StiL NHL1 study bendamustine plus rituximab (B-R) versus CHOP plus rituximab (CHOP-R) as first-line treatment in patients with indolent lymphomas
    Rummel, M. J.
    Maschmeyer, G.
    Ganser, A.
    Heider, A.
    von Gruenhagen, U.
    Losem, C.
    Heil, G.
    Welslau, M.
    Balser, C.
    Kaiser, U.
    Weidmann, E.
    Duerk, H. A.
    Ballo, H.
    Stauch, M.
    Blau, W.
    Burchardt, A.
    Barth, J.
    Kauff, F.
    Brugger, W.
    ONCOLOGY RESEARCH AND TREATMENT, 2017, 40 : 73 - 73
  • [10] Bendamustine Plus Rituximab (B-R) Versus CHOP Plus Rituximab (CHOP-R) As First-Line Treatment in Patients with Indolent and Mantle Cell Lymphomas (MCL)-7 Year Updated Results from the StiL NHL1 Study
    Rummel, Mathias J.
    Maschmeyer, Georg
    Ganser, Arnold
    Heider, Andrea
    von Gruenhagen, Ulrich
    Losem, Christoph
    Heil, Gerhard
    Welslau, Manfred
    Balser, Christina
    Kaiser, Ulrich
    Weidmann, Eckhart
    Duerk, Heinz
    Boeck, Hans Peter
    Stauch, Martina Beate
    Barth, Juergen
    Blau, Wolfgang
    Burchardt, Alexander
    Kauff, Frank
    Hinke, Axel
    Brugger, Wolfram
    BLOOD, 2014, 124 (21)
12345